Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comment on: "Cell Therapy for Heart Disease: Trial Sequential Analyses of Two Cochrane Reviews"

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The mitochondria in heart failure: a target for coenzyme Q10 therapy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Antipsychotics and associated risk of out-of-hospital cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Acupuncture for chronic hepatitis B

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exercise-Based Rehabilitation for Heart Failure: Cochrane Systematic Review, Meta-Analysis, and Trial Sequential Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

OriginalsprogEngelsk
TidsskriftClinical Pharmacology and Therapeutics
Vol/bind104
Udgave nummer4
Sider (fra-til)606-609
ISSN0009-9236
DOI
StatusUdgivet - 13 jul. 2018

ID: 54833158